Abgenix‚ Inc. begins operations in Fremont‚ California as a subsidiary of Cell Genesys. C. Geoffrey Davis is the co-founder and Chief Scientific Officer; R. Scott Greer is the Chief Executive Officer. Abgenix undertakes research on immunotherapies for wide range of maladies including autoimmune disorders‚ infectious diseases‚ cardiovascular disease‚ and transplant rejection‚ but its big breakthrough is made in antibody production technology. Abgenix‚ Inc. has managed to “invented” XenoMouse‚
Premium DNA Immune system Disease
Introduction: Abgenix was a company founded in California who had a unique method for generating antibodies useful in treating a number of diseases‚ one of which was cancer. They named this unique method XenoMouse. Abgenix spent 7 years and $40 million to produce XenoMouse which was a genetically engineered mouse which could produce antibodies that would treat illnesses like cancer‚ transplant rejection and inflammation. B. Abgenix Ways To Generate Revenue: Abgenix generated revenues
Premium Clinical trial Food and Drug Administration Drug development
Harvard Business School 9-501-061 January 9‚2001 Abgenix and the XenoMouse Meet XenoMouse "Meet XenoMoussrl\4/’headlined the piece frorn the Abgenix information kit. (See Exhibit 1.) wortl-r meeting‚ XenoMouse was probably it. While Lee Majors played bionic rnan‚ Steven Austin‚ in the popular Six Milliott Dollar Man television series in the 1970s‚ XenoMouse could well be termed the "Three Billion Dollar Mouse." XenoMouse lived at Abgenix in Frernont‚ California‚ just across the Dunbarton Bridge
Premium Clinical trial Cancer
In April 2000‚ the biopharmaceutical company Abgenix faced the important strategic decision of how to most profitably commercialize its XenoMouse based high potential cancer product ABX-EGF‚ which had reached phase I clinical trials after having successfully passed preclinicals. Specifically‚ Abgenix had to choose among three salient alternatives for the route to market of ABX-EGF. These were: 1. Entering into a licensing agreement with “Big Pharma” Pharmacol‚ yielding a series of development
Premium Clinical trial
XenoMouse: Produces antibodies for disease targets Benefits: Longer therapy‚ fewer side effects‚ faster drug development Abgenix & the Xenomouse 1 Case Questions • Which of the three alternatives would you recommend to the company? 1. A Pharmacol “hand-off” deal (who is Pharmacol)? 2. A Biopart “hand-in” deal (who is Biopart)? 3. “Go-it-alone” through Phase II & then decide a development strategy? • What are the direct financial implications of your answer? • What are the strategic
Premium Clinical trial
significant risks for a drug company. Startups often lack the financial resources and expertise to shoulder alone the risks of such process‚ let alone in situations where they have not gone through this process before. Collaboration would allow Abgenix to obtain rapid access to complementary assets -- the skills and resources of its collaboration partner to through the testing and regulatory process‚ and the commercial launching and marketing of the drug afterwards. As a result‚ ABX-EGF can significantly
Premium Drug development Pharmaceutical industry Firm
SWOT Analysis Strengths Interestingly‚ the company claims that its core strength is derived from its outstanding portfolio of products‚ its global reach and‚ above all‚ the creativity and commitment of its employees. It has ten products each with global sales of over $1 billion i.e. products such as Nexium‚ Seroquel‚ Crestor‚ Arimidex and Symbicort (2005). The global reach of the company is also becoming strong‚ as it is starting to show signs of success in China‚ growing their business there
Premium
Chapter 7 * Why do we want to make Eukaryotic cell proteins? * Because when eukaryotic proteins are expressed in prokaryotic cells problems like been unstable‚ no biological activity and prokaryotic contaminants ( pyrogens) can occur. * Also to make the protein as natural as possible * The same expression vectors as we need for pro * We don’t need shangdolron coz that only for pro Transformation: in Eukaryotic cells: in humans means that difference in growth characters
Premium DNA Bacteria Cell nucleus
Merge che rs & Ac AstraZ eneca Sapom p Wohnb au quisiti J&J Ardea Bioscie n ons of Abbott ces the Top 20 in th Eli Lilly Astra T ech Bayer Synthe s Novex el uest Pirama Acclare l nt Couga Solvay r Mento OMRIX Conor Medsy s Talecri s ICOS TheraS Abbott Invern es Medtec s h ALZA BASF Bayer Foods IVAX SS AG a ca Centoc or ix 20 nco Medise Anima 60 0 20 40 Pharm a Delta P harma g Ops h BU STEAG Vaccin e Man. Plant FH Fau lding BMS O US&Ca
Premium Pharmaceutical industry Mergers and acquisitions Novartis
Business Source Complete Other Sources (Book / Monograph‚ Case Study‚ Conference Papers Collection‚ Conference Proceedings Collection‚ Country Report‚ Financial Report‚ Government Document‚ Grey Literature‚ Industry Report‚ Law‚ Market Research Report‚ Newspaper‚ Report‚ SWOT Analysis‚ Video‚ Working Paper‚ etc.) *Titles with ’Coming Soon’ in the Availability column indicate that this publication was recently added to the database and therefore few or no articles are currently available. If
Premium Management Business school Harvard Business School